Minerva Neurosciences Inc. (Nasdaq: NERV) reported positive results from a
Phase IIb trial of MIN-101 to treat patients with negative symptoms of
schizophrenia. Shares of the biopharmaceutical nearly tripled by leaping $6.76 to $10.30.
Positive trial results for Minerva Neurosciences
May 26, 2016 at 13:42 PM EDT
